HWHG(SH:600079) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-02 23:37Group 1 - Company received drug registration certificate for Eicosapentaenoic Acid Ethyl Ester Soft Capsules from the National Medical Products Administration [1][2] - The product is indicated for lowering triglyceride levels in adult patients with severe hypertriglyceridemia and for reducing cardiovascular event risks in patients with cardiovascular diseases or diabetes [2][3] - Cumulative R&D investment for the product is approximately RMB 6 million, with projected national sales of around RMB 5 million for 2024 [2] Group 2 - Company also received drug registration certificate for Levophed Injection, which is used for blood pressure control in acute hypotensive states [6][7] - Cumulative R&D investment for Levophed Injection is approximately RMB 5 million, with projected national sales of around RMB 2.1 billion for 2024 [7] - Both products enhance the company's product line and are expected to have a positive impact on sales, although future sales may be influenced by industry policies and market conditions [3][7]